SCHEMBL21922406

SCHEMBL21922406

CCN1CCN(CCNc2nccc(-c3c(-c4ccc(F)c(OC)c4)nc4occn34)n2)S1(=O)=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 18/20 0.72
RAF1 P04049 9/20 0.72
EGFR P00533 4/20 0.72
MAPK8 P45983 2/20 0.47
ERN1 O75460 1/20 0.47
ABL1 P00519 1/20 0.47
FGFR1 P11362 1/20 0.47
FLT3 P36888 1/20 0.47
MAPK11 Q15759 1/20 0.47
MAPK14 Q16539 1/20 0.47
NTRK2 Q16620 1/20 0.47
HIPK1 Q86Z02 1/20 0.47
MAP3K20 Q9NYL2 1/20 0.47
PRKD3 O94806 1/20 0.45
MAP4K4 O95819 1/20 0.45
MAPK9 P45984 1/20 0.45
CSNK1A1 P48729 1/20 0.45
CSNK1D P48730 1/20 0.45
GSK3B P49841 1/20 0.45
CSNK1G2 P78368 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21922212 0.97 BRAF (0.68) BRAFRAF1EGFR
SCHEMBL21923128 0.94 BRAF (0.71) BRAFRAF1EGFRMAPK8ERN1
SCHEMBL21922364 0.91 BRAF (0.72) BRAFRAF1EGFRMAPK8ERN1
SCHEMBL21922411 0.91 BRAF (0.65) BRAFRAF1EGFRMAPK8ERN1
SCHEMBL21922417 0.90 BRAF (0.79) BRAFRAF1EGFRMAPK8ERN1
SCHEMBL21923129 0.89 BRAF (0.68) BRAFRAF1EGFRMAPK8ERN1
SCHEMBL20969771 0.88 BRAF (0.75) BRAFRAF1EGFRMAPK8ERN1
SCHEMBL21922391 0.88 BRAF (0.61) BRAFRAF1EGFR
SCHEMBL21922402 0.87 BRAF (0.74) BRAFRAF1EGFRMAPK8ERN1
SCHEMBL20969828 0.87 BRAF (0.81) BRAFRAF1EGFRMAPK8ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332479-B2 Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-05-17 US disclosed
EP-3845539-A1 IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Korea Institute of Science and Technology (KR) 2021-07-07 EP disclosed
US-20200131199-A1 IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200131199-A1 IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME TPMT, MYD88, IDO1 BRAF 159/4885RAF1 978/4885EGFR 2278/4885
US-11332479-B2 Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same TPMT, MYD88, IDO1 BRAF 159/4885RAF1 978/4885EGFR 2278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.